Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944839 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
A Phase 3 study, sponsored by Ophthotech Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 619
- Enrollment target
NCT01944839: Clinical Trial Phase 3 study, sponsored by Ophthotech Corporation.
NCT01944839 is a Phase 3 study that was terminated before completion, run by Ophthotech Corporation. The registered enrollment target is 619 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01944839, a Phase 3 study, was terminated before completion, sponsored by Ophthotech Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 619 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Primary Outcome
The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from baseline to the month 12 visit. Higher ETDRS letters represents higher vision and a higher change in ETDRS letters represents better functioning.
Interventions
- DRUG ranibizumab
- DRUG E10030
- DRUG E10030 sham intravitreal injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 619 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Why NCT01944839 stopped before completion
NCT01944839 is an interventional study that assigns participants to a tested intervention. The registered 619 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT01944839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01944839 about?
NCT01944839 is a clinical study titled "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy". The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT01944839?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 619 participants. The study started on 2013-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01944839?
The interventions under investigation include: ranibizumab (DRUG), E10030 (DRUG), E10030 sham intravitreal injection (DRUG).
Who is sponsoring clinical trial NCT01944839?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01944839's enrollment target sits among peer trials
619 591st of 2000 higher than 1,410 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia